文献速递前列腺癌

帕博利珠单抗联合恩扎卢胺治疗经阿比特龙醋酸酯预治疗的转移性去势抵抗性前列腺癌患者:KEYNOTE-365 研究 1b/2 期 C 队列

Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate-Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 Study.
PubMed 文献 · Eur Urol Oncol · 2023-11-07

KEYNOTE-365 研究 C 队列纳入 102 例经阿比特龙醋酸酯治疗失败或不耐受的转移性去势抵抗性前列腺癌患者,接受帕博利珠单抗 200 mg 静脉每 3 周联合恩扎卢胺 160 mg 口服每日一次。确诊 PSA 缓解率 24%(95%CI 16-33%),确诊客观缓解率 11%(95%CI 2.9-25%,4/38 例,含 2 例完全缓解),中位影像学无进展生存期 6.0 个月(95%CI 4.1-6.3),中位总生存期 20 个月(95%CI 17-24)。治疗相关不良事件发生率 92%(94 例),3-5 级治疗相关不良事件发生率 43%(44 例),1 例(1.0%)死于治疗相关不良事件。

要点

  • 确诊 PSA 缓解率 24%(95%CI 16-33%),确诊客观缓解率 11%(95%CI 2.9-25%)。
  • 中位影像学无进展生存期 6.0 个月(95%CI 4.1-6.3),中位总生存期 20 个月(95%CI 17-24)。
  • 治疗相关不良事件 94 例(92%),3-5 级 44 例(43%),1 例(1.0%)死于治疗相关不良事件。

核心结论

  • 帕博利珠单抗联合恩扎卢胺在既往接受阿比特龙治疗但未接受化疗的 mCRPC 患者中抗肿瘤活性有限,安全性特征与各单药已知安全性一致。

研究设计与样本

  • 1b/2 期 KEYNOTE-365 研究 C 队列,纳入 102 例接受阿比特龙醋酸酯治疗≥4 周后治疗失败或不耐受的化疗前 mCRPC 患者。

主要发现

  • 确诊 PSA 缓解率 24%(95%CI 16-33%)。
  • 确诊客观缓解率 11%(95%CI 2.9-25%;4/38 例;2 例完全缓解)。
  • 中位影像学无进展生存期 6.0 个月(95%CI 4.1-6.3)。
  • 中位总生存期 20 个月(95%CI 17-24)。
  • 治疗相关不良事件 94 例(92%);3-5 级治疗相关不良事件 44 例(43%);1 例(1.0%)死于治疗相关不良事件(原因未知)。

关键数值与推荐

  • 干预方案:帕博利珠单抗 200 mg 静脉每 3 周联合恩扎卢胺 160 mg 口服每日一次。
  • 主要终点:安全性、确诊 PSA 缓解率、盲法独立中心评审(BICR)按 RECIST 1.1 评估的客观缓解率。
  • 次要终点:BICR 评估的影像学无进展生存期和总生存期。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 研究局限性包括单臂设计。
  • 联合治疗中治疗相关皮疹的发生率高于各单药安全性特征预期。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Limited responses have been observed in patients treated with enzalutamide after disease progression on abiraterone for metastatic castration-resistant prostate cancer (mCRPC), but androgen receptor signaling impacts T-cell function. OBJECTIVE: To evaluate the efficacy and safety of pembrolizumab plus enzalutamide in mCRPC. DESIGN, SETTING, AND PARTICIPANTS: Patients in cohort C of the phase 1b/2 KEYNOTE-365 study, who received ≥4 wk of treatment with abiraterone acetate in the prechemotherapy mCRPC state and experienced treatment failure or became drug-intolerant, were included. INTERVENTION: Pembrolizumab 200 mg intravenously every 3 wk plus enzalutamide 160 mg orally once daily. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoints were safety, the confirmed prostate-specific antigen (PSA) response rate, and the objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumors version 1.1 on blinded independent central review (BICR). Secondary endpoints included radiographic progression-free survival (rPFS) on BICR and overall survival (OS). RESULTS AND LIMITATIONS: A total of 102 patients received pembrolizumab plus enzalutamide. Median follow-up was 51 mo (interquartile range 37-56). The confirmed PSA response rate was 24% (95% confidence interval [CI] 16-33%). The confirmed ORR was 11% (95% CI 2.9-25%; 4/38 patients; two complete responses). Median rPFS was 6.0 mo (95% CI 4.1-6.3). Median OS was 20 mo (95% CI 17-24). Treatment-related adverse events (TRAEs) occurred in 94 patients (92%); grade 3-5 TRAEs occurred in 44 patients (43%). The incidence of treatment-related rash was higher with combination therapy than expected from the safety profile of each drug. One patient (1.0%) died of a TRAE (cause unknown). Study limitations include the single-arm design. CONCLUSIONS: Pembrolizumab plus enzalutamide had limited antitumor activity in patients who received prior abiraterone treatment without previous chemotherapy for mCRPC, with a safety profile consistent with the individual profiles of each agent. PATIENT SUMMARY: Pembrolizumab plus enzalutamide showed limited antitumor activity and manageable safety in patients with metastatic castration-resistant prostate cancer. The KEYNOTE-365 trial is registered on ClinicalTrials.gov as NCT02861573.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Yu EY, Berry WR, Gurney H, et al. Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate-Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 Study. Eur Urol Oncol. 2023. PMID: 37940446. doi:10.1016/j.euo.2023.10.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。